Better immune response from mixing Covaxin, Covishield, says ICMR study | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
July 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JULY 12, 2025
Better immune response from mixing Covaxin, Covishield, says ICMR study

Coronavirus chronicle

UNB
09 August, 2021, 03:15 pm
Last modified: 09 August, 2021, 04:29 pm

Related News

  • Serum Institute, Bill Gates get Bombay high court notice as petitioner claims Covishield killed his daughter
  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin

Better immune response from mixing Covaxin, Covishield, says ICMR study

While Covishield is built on a viral vector vaccine platform and uses a weakened version of adenovirus, a common cold virus that causes infection in chimpanzees, Covaxin is built on an inactivated whole virus vaccine platform

UNB
09 August, 2021, 03:15 pm
Last modified: 09 August, 2021, 04:29 pm
The study found that immunisation with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity. Photo: UNB
The study found that immunisation with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity. Photo: UNB

A GROUP of 18 people, who had "inadvertently received Covishield as the first jab and Covaxin as the second", showed better immunogenicity — the ability to generate an immune response — than those who received two doses of the same vaccine, according to a new study by the Indian Council of Medical Research (ICMR), reports The Indian Express.

In May, 18 villagers in Siddarthnagar, Uttar Pradesh, had received Covaxin as the second dose, six weeks after they got Covishield. The study compared their reaction to 40 recipients of two doses of Covishield and 40 recipients of two doses of Covaxin.

"We compared the safety and immunogenicity profile of them (the group of 18) against that of individuals receiving either Covishield or Covaxin. Lower and similar adverse events following immunisation in all three groups underlined the safety of the combination vaccine-regime," said the study which is yet to be peer reviewed.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"Immunogenicity profile against Alpha, Beta and Delta variants in the heterologous group was superior; IgG antibody and neutralising antibody response of the participants was also significantly higher compared to that in the homologous groups," it said.

"Overall, this study demonstrates that immunisation with a heterologous combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine is safe and elicits better immunogenicity than two doses of homologous vaccination, using the same vaccines," it said.

While Covishield is built on a viral vector vaccine platform and uses a weakened version of adenovirus, a common cold virus that causes infection in chimpanzees, Covaxin is built on an inactivated whole virus vaccine platform.

The study is the first scientific evidence emerging from India on superior immunogenicity profile demonstrated in mixed-vaccine doses. However, the researchers have underlined that to conclusively prove these preliminary findings, "multi-centre" randomised control trials need to be carried out. They have also flagged the study's limitations: the sample size of 18 participants is small; follow-up period is only 60-70 days after first dose; baseline serological and immunological data of participants is not available.

According to the study, the findings have an "important implication" for the Covid-19 vaccination programme wherein "heterologous immunisation will pave the way for induction of improved and better protection against the variant strains of SARS-CoV-2".

"This is the first report of heterologous immunisation with an adenovirus vector based and an inactivated whole virion vaccine in humans demonstrating safety and significantly improved immunogenicity… Immunogenicity profile studied against the variants of concerns, Alpha, Beta and Delta variants, demonstrates significantly higher titers in the heterologous group," it said.

The researchers have said such mixed regimens will help to "overcome the challenges of shortfall of particular vaccines" and "remove hesitancy around vaccines in people's mind that could have genesis in programmatic 'errors' especially in settings where multiple Covid-19 vaccines are being used".

On safety, reactogenicity analysis showed that in the heterologous group, 11 per cent reported pain at the injection site; however, during the second dose, no such local adverse event was reported, it said.

The most commonly reported systemic adverse event was pyrexia (raised body temperature) and malaise (discomfort): 33.3 per cent reported this during the first dose, and 5.5 percent during the second dose. "No other systemic AEFI like, urticaria, nausea, vomiting, arthralgia or cough was reported," said the study.

Currently, the Indian drug regulator has granted permission to CMC Vellore to conduct Phase 4 clinical trials to assess the efficacy of a combination of Covishield and Covaxin doses as compared to the current protocol of using two doses of the same vaccine

Top News / World+Biz

COVAXIN / Covishield / ICMR

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • File photo: Demonstration of teachers/Collected
    Primary teachers call for pay scale reform, promotions during regional conference in Ctg
  • A file photo of BNP acting chairman Tarique Rahman speaking virtually at a party programme. Photo: Collected
    Why is govt allowing this?: Tarique calls for crackdown on mob violence
  • Bangladesh and US hold tariff talks on 11 July 2025. Photo: CA Press Wing
    Dhaka, Washington yet to agree on 20% of US tariff conditions: BGMEA

MOST VIEWED

  • Representational image
    In addition to 35% tariff, US demands 40% local value addition for 'Made in Bangladesh' goods
  • Screengrab blurred
    Killers bash in head of man with rock, stomp body with perverse pleasure
  • How tender rules and a lone bidder stall a $2.5b power plant
    How tender rules and a lone bidder stall a $2.5b power plant
  • Economist Abul Barkat; Photo: Courtesy
    Economist Abul Barkat arrested in graft case
  • Photo: UNB
    Saima Wazed Putul ‘placed on indefinite leave’ from WHO role amid corruption allegations
  • After India's visa restriction, China's Kunming is drawing Bangladeshi patients
    After India's visa restriction, China's Kunming is drawing Bangladeshi patients

Related News

  • Serum Institute, Bill Gates get Bombay high court notice as petitioner claims Covishield killed his daughter
  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin

Features

The 2020 Harrier's Porsche Cayenne coupe-like rear roofline, integrated LED lighting with the Modellista special bodykit all around, and a swanky front grille scream OEM Plus for the sophisticated enthusiast looking for a bigger family car that isn’t boring. PHOTO: Ahbaar Mohammad

2020 Toyota Harrier Hybrid: The Japanese Macan

3h | Wheels
The showroom was launched through a lavish event held there, and in attendance were DHS Motors’ Managing Director Nafees Khundker, CEO Imran Zaman Khan, and GMs Arman Rashid and Farhan Samad. PHOTO: Akif Hamid

GAC inaugurate flagship showroom in Dhaka

4h | Wheels
After India's visa restriction, China's Kunming is drawing Bangladeshi patients

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

1d | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

1d | The Big Picture

More Videos from TBS

Flashpoint Cumilla: where the July coup turned violent

Flashpoint Cumilla: where the July coup turned violent

1h | TBS Stories
US-Canada trade talks still uncertain

US-Canada trade talks still uncertain

3h | TBS World
Air India crash: What happened before the plane crashed?

Air India crash: What happened before the plane crashed?

5h | TBS World
Home Affairs Advisor calls on everyone to come forward and stop violence

Home Affairs Advisor calls on everyone to come forward and stop violence

6h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net